UK Next-generation Sequencing Market

The UK next-generation sequencing market is projected to grow from USD 795.8 million in 2026 to USD 1,587.2 million by 2031, at a CAGR of 14.8% during the forecast period.

The UK next-generation sequencing market is expanding rapidly due to significant advancements in genomic research capabilities, increased government and institutional funding for precision medicine initiatives, growing clinical applications across oncology and rare disease diagnostics, and rising demand for cost-effective, high-throughput sequencing solutions that support personalized healthcare delivery.

To know about the assumptions considered for the study download the pdf brochure

The UK next-generation sequencing market is dominated by major players, including Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Oxford Nanopore Technologies plc. (UK), Agilent Technologies, Inc. (US), and QIAGEN (Netherlands). Leading next-generation sequencing players stay competitive by launching advanced sequencing platforms with enhanced throughput and accuracy, adopting AI and ML for data analysis workflows, refining long-read sequencing technologies, forming strategic partnerships with healthcare institutions and research organizations, and delivering faster, cost-efficient, regulatory-compliant sequencing solutions across clinical diagnostics, research, and pharmaceutical sectors.

Illumina (US) is a leading provider of next-generation sequencing platforms and consumables serving clinical and research applications globally, with a strong presence in the UK market. Its comprehensive portfolio of sequencing systems, including the NovaSeq X series, combines high-throughput capacity with improved accuracy and reduced sequencing costs, enabling large-scale genomic studies and routine clinical diagnostics. The company delivers a full suite of products and services, including sequencing instruments, reagent kits, bioinformatics software, and technical support for applications spanning oncology, reproductive health, genetic disease research, and population genomics. With decades of experience and continuous innovation in sequencing chemistry and platform development, Illumina has established itself as a trusted partner for academic institutions, healthcare providers, and pharmaceutical companies across the country.

Thermo Fisher Scientific (US) is a technology-driven life sciences company specializing in integrated sequencing solutions for clinical diagnostics, translational research, and applied genomics markets in the UK and Europe. Combining instrument platforms, consumables, and bioinformatics tools into a single end-to-end workflow, Thermo Fisher significantly reduces complexity, turnaround time, and operational costs compared to fragmented sequencing approaches. The company’s ion torrent and other sequencing technologies enable scalable applications from targeted gene panels to whole genome sequencing, offering substantial workflow efficiency, data quality, and regulatory compliance. Thermo Fisher's comprehensive service offerings, including sample preparation reagents, sequencing instruments, data analysis software, and validation support, provide researchers and clinicians with turnkey solutions that accelerate discovery and diagnostic implementation without compromising accuracy.

MARKET RANKING

Illumina (US), Thermo Fisher Scientific (US), and Oxford Nanopore Technologies plc. (UK) are the leading companies in the UK next-generation sequencing market. Illumina is recognized for high-throughput short-read sequencing platforms and comprehensive consumable portfolios supporting clinical diagnostics and large-scale research projects, backed by continuous innovation in sequencing chemistry and bioinformatics. Thermo Fisher Scientific specializes in scalable semiconductor-based sequencing systems and integrated workflows, combining instruments, reagents, and software for targeted and whole genome applications across clinical and research settings. Oxford Nanopore Technologies is known for its portable, real-time long-read sequencing devices and nanopore-based technology, enabling flexible, on-demand sequencing for research, clinical, and field applications with minimal infrastructure requirements.

Related Reports:

UK Next-generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Application, Competition - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com